Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06984627 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06984627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06984627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
September 2, 2025
Completion date
March 11, 2027
Enrollment
30 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

graves' disease